PRNewsWire
16 Feb 2026, 22:31 UTC · 30w ago
Verdict
Headline leans bullish. We score LLY +0.80 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Amgen and Kyowa Kirin's Rocatinlimab has completed recruitment for its Phase III ROCKET program, involving over 3,300 participants.
More positive than 91% of claims this week
Sanofi and Kymab's Amlitelimab is currently in Phase III clinical development for moderate-to-severe atopic dermatitis.
Continue reading
5 related stories
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 76% of claims this week
Eli Lilly is positioned to capture significant market share in the EU4, UK, and Japan using Olumiant and Ebglyss.
More positive than 64% of claims this week
Dupixent is predicted to maintain market dominance in the atopic dermatitis sector for the next 10 years or more.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Poised to emerge as a key player with significant market share potential for OLUMIANT and EBGLYSS.
More positive than 74% of ticker scores this week
Developing Amlitelimab, which holds promise as a first- or best-in-class therapy currently in Phase III.
More positive than 74% of ticker scores this week
Developing Rocatinlimab with Phase III recruitment complete, representing a potential first-in-class therapy.
More positive than 63% of ticker scores this week
Listed as a pharmaceutical company developing therapies for atopic dermatitis.
More positive than 63% of ticker scores this week
Listed as a pharmaceutical company developing therapies for atopic dermatitis.
More positive than 63% of ticker scores this week
Listed as a pharmaceutical company developing therapies for atopic dermatitis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
23h ago
More positive than 57% of relationship scores this week
[mutual] Sanofi and Kymab are collaborating on the development of Amlitelimab.
More positive than 35% of relationship scores this week
[mutual] Roche and Eli Lilly both develop therapies for atopic dermatitis.
More positive than 35% of relationship scores this week
[mutual] Eli Lilly and Sanofi compete in the atopic dermatitis treatment market.
More positive than 35% of relationship scores this week
[mutual] Eli Lilly and Amgen compete in the atopic dermatitis treatment market.
More positive than 35% of relationship scores this week
[mutual] Both companies are developing and marketing therapies for atopic dermatitis.
+10.3%
Price agrees with the score
$1147.25 vs $1040.00 close before publication (Feb 13) · not market-adjusted
LLY chart →
